Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 518 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Tenofovir DF Clear all
Completed Phase 2 Interventional

Safety and Effectiveness of Adding PMPA Prodrug to an Anti-HIV Drug Combination to Treat HIV-Infected Patients

NCT00002415
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir disoproxil fumarate
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 2, 2026, 1:03 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

NCT01108510
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
COBI, RTV, ATV, FTC/TDF, COBI placebo, RTV placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
64
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated May 22, 2016 · Synced Sep 2, 2026, 1:03 PM EDT
Completed No phase listed Observational

Long-term Study on Anti-HBV Effect of Tenofovir and Resistance Surveillance in Asian-American Adult Patients

NCT01267162
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Not listed
Lead sponsor
Medical Procare PLLC
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Los Angeles, California • San Jose, California • Flushing, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Sep 2, 2026, 1:03 PM EDT
Completed Phase 4 Interventional Results available

Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine

NCT04538040
View directory record Official record
Conditions
HIV-1-infection
Interventions
Bictegravir/emtricitabine/tenofovir alafenamide + Doravirine switch
Drug
Lead sponsor
Quest Clinical Research
Other
Eligibility
45 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Sep 2, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

A Study to Compare Tenofovir DF Versus the Combination of Emtricitabine Plus Tenofovir DF for the Treatment of Chronic Hepatitis B in Patients With Normal Alanine Aminotransferase (ALT)

NCT00507507
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Tenofovir DF, FTC, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 69 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
10
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2015 · Synced Sep 2, 2026, 1:03 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring (TDF IVR-002)

NCT02762617
View directory record Official record
Conditions
Healthy, HIV
Interventions
Tenofovir disoproxil fumarate intravaginal ring, Placebo intravaginal ring (IVR)
Drug
Lead sponsor
Marla Keller
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Sep 2, 2026, 1:03 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Botswana TDF/FTC Oral HIV Prophylaxis Trial

NCT00448669
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg, Placebo Oral Tablet
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 39 Years
Enrollment
1,219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 2, 2026, 1:03 PM EDT
Terminated Phase 2 Interventional Results available

A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection

NCT05005507
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
JNJ-73763989, PegIFN-alpha-2a, Tenofovir disoproxil, TAF, ETV
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Hillsborough, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Sep 2, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV

NCT00949234
View directory record Official record
Conditions
HIV Prevention, HIV Infections
Interventions
tenofovir + emtricitabine, lopinavir/ritonavir
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2017 · Synced Sep 2, 2026, 1:03 PM EDT
Terminated Phase 2 Interventional Results available

Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV

NCT00090779
View directory record Official record
Conditions
HIV Infections
Interventions
Emtricitabine/ tenofovir disoproxil fumarate, Lopinavir/Ritonavir
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
25
States / cities
San Diego, California • San Francisco, California • Torrance, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Sep 2, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men

NCT00131677
View directory record Official record
Conditions
HIV Infection
Interventions
tenofovir disoproxil fumarate, placebo
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 60 Years · Male only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
3
States / cities
San Francisco, California • Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2014 · Synced Sep 2, 2026, 1:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, PK, and PD Study of a Vaginal Insert Containing TAF and EVG

NCT03762772
View directory record Official record
Conditions
Hiv, HSV
Interventions
TAF/EVG Vaginal Insert
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Sep 2, 2026, 1:03 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

NCT01968551
View directory record Official record
Conditions
HIV-1, HIV Infections, Acquired Immunodeficiency Syndrome
Interventions
E/C/F/TAF, DRV, Baseline DRV- containing ARV regimen
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
56
States / cities
Phoenix, Arizona • Beverly Hills, California • Hayward, California + 43 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 2, 2026, 1:03 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

NCT01106586
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
Stribild, ATV, Ritonavir, FTC/TDF, Stribild Placebo, ATV Placebo, RTV Placebo, FTC/TDF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
708 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
86
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 57 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Sep 2, 2026, 1:03 PM EDT
Completed No phase listed Observational

Evaluation of Albuminuria HIV-Infected Patients

NCT00524992
View directory record Official record
Conditions
HIV-Associated Focal Segmental Glomerulosclerosis, HIV-Associated Collapsing Glomerulopathy, Proteinuria, Albuminuria, Renal Tubular Toxicity
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Sep 2, 2026, 1:03 PM EDT
Completed No phase listed Observational Results available

Comparison of Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive Adults

NCT02218320
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Raltegravir, Dolutegravir, Colonoscopy with biopsy
Drug · Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 25, 2018 · Synced Sep 2, 2026, 1:03 PM EDT
Not yet recruiting Not applicable Interventional

Supporting Health and Empowerment Through Contingency Management and Affect Regulation

NCT07792161
View directory record Official record
Conditions
HIV Risk
Interventions
urine-based self-test, urine-based clinic test
Diagnostic Test
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 2, 2026, 1:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Quantification of Estradiol's Impact on Nucleotides in Cellular Populations of the Lower GI Tract

NCT03917420
View directory record Official record
Conditions
HIV/AIDS
Interventions
Tenofovir 300Mg Oral Tablet, Emtricitabine 200 MG
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Sep 2, 2026, 1:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Microbicide Safety and Acceptability in Young Men

NCT01283360
View directory record Official record
Conditions
High Risk MSM, HIV Negative, 18-30 Years of Age
Interventions
HEC Placebo Gel, Tenofovir 1% Gel
Other · Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Sep 2, 2026, 1:03 PM EDT
Approved For Marketing No phase listed Expanded access

Treatment on HBeAg Positive or HBeAg Negative in Chronic Hepatitis B

NCT01198860
View directory record Official record
Conditions
CHRONIC HEPATITIS B
Interventions
CTH Chronic Hepatitis B
Drug
Lead sponsor
Nguyen Thi Trieu, MD
Individual
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 2, 2026, 1:03 PM EDT
Completed Phase 4 Interventional Results available

Parrying the Pitfalls of PrEP: Project PEACH

NCT05072093
View directory record Official record
Conditions
HIV, STI
Interventions
PrEP discontinuation intervention, Offering of on-demand oral PrEP, Offering of STI PEP, Injectable PrEP
Behavioral · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 2, 2026, 1:03 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men

NCT00458393
View directory record Official record
Conditions
HIV Infections
Interventions
daily TDF/FTC, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Male only
Enrollment
2,499 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Sep 2, 2026, 1:03 PM EDT
Completed Phase 2 Interventional

A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation

NCT00036452
View directory record Official record
Conditions
HIV Infections
Interventions
lopinavir/ritonavir, emtricitabine, stavudine, tenofovir DF
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
27
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 2, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

CROSSOVER STUDY OF ON-DEMAND PREP FORMULATIONS COMPARING RECTAL AND ORAL TENOFOVIR

NCT06560684
View directory record Official record
Conditions
Tenofovir
Interventions
Oral F/TDF Pills, TFV rectal douche
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Lawrenceville, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 2, 2026, 1:03 PM EDT